In Brief: Atrix Labs Atridox
Executive Summary
Atrix Labs Atridox: Doxycycline polymer delivery system for periodontal disease to be filed in early 1997, Fort Collins, Colo.-based Atrix says. Atridox shows clinical and statistical superiority to placebo and equivalence to mechanical scaling and route planing in Phase III trials, the firm reports Aug. 26. Atridox is "applied to the infected periodontal pocket as a fluid, where it molds to the shape of the problem area and quickly solidifies, releasing the drug" for a week, Atrix reports. The drug was studied in 758 subjects over nine months...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth